Evicenter
P&T meetings

Duravyu

Wet age-related macular degeneration

Also known as vorolanib intravitreal insert, EYP-1901
Manufacturer
EyePoint
Launch
Not announced
136 sources

Section 6 of 6

References

136 sources

  1. Abbey (2026) (opens in a new tab)
  2. Abbey and Ribeiro (2025) (opens in a new tab)
  3. Abu Al-Burak et al. (2026) (opens in a new tab)
  4. Al-Khersan et al. (2022) (opens in a new tab)
  5. Almony et al. (2021) (opens in a new tab)
  6. American Academy of Ophthalmology (2024) (opens in a new tab)
  7. Bakri et al. (2024) (opens in a new tab)
  8. Baljoon et al. (2026) (opens in a new tab)
  9. Brown et al. (2000) (opens in a new tab)
  10. Brown et al. (2016) (opens in a new tab)
  11. Brown et al. (2020) (opens in a new tab)
  12. Brown et al. (2021) (opens in a new tab)
  13. Brown et al. (2024) (opens in a new tab)
  14. Bryan et al. (2025) (opens in a new tab)
  15. Butt et al. (2017) (opens in a new tab)
  16. Chambers et al. (2025) (opens in a new tab)
  17. Chu et al. (2024) (opens in a new tab)
  18. Ciulla et al. (2020) (opens in a new tab)
  19. ClinicalTrials.gov NCT01674569 (opens in a new tab)
  20. ClinicalTrials.gov NCT01674569 (opens in a new tab)
  21. ClinicalTrials.gov NCT02348359 (opens in a new tab)
  22. ClinicalTrials.gov NCT02348359 (opens in a new tab)
  23. ClinicalTrials.gov NCT04747197 (opens in a new tab)
  24. ClinicalTrials.gov NCT05381948 (opens in a new tab)
  25. ClinicalTrials.gov NCT05381948 (opens in a new tab)
  26. ClinicalTrials.gov NCT05381948 (opens in a new tab)
  27. ClinicalTrials.gov NCT06668064 (opens in a new tab)
  28. ClinicalTrials.gov NCT06683742 (opens in a new tab)
  29. CMS Medicare Part B Payment Limit File (2026) (opens in a new tab)
  30. CMS Medicare Part B Spending by Drug (2026) (opens in a new tab)
  31. Cohen et al. (2021) (opens in a new tab)
  32. Congdon et al. (2004) (opens in a new tab)
  33. Csaky et al. (2008) (opens in a new tab)
  34. Dang et al. (2024) (opens in a new tab)
  35. Daniel et al. (2014) (opens in a new tab)
  36. Delcourt et al. (2026) (opens in a new tab)
  37. Dhoot (2025) (opens in a new tab)
  38. Dickson and James (2023) (opens in a new tab)
  39. Dinah and Ribeiro (2025) (opens in a new tab)
  40. Duker (2026) (opens in a new tab)
  41. Eichenbaum et al. (2025) (opens in a new tab)
  42. EyePoint DSMC recommendation announcement (2026) (opens in a new tab)
  43. EyePoint Form 10-K (2026) (opens in a new tab)
  44. EyePoint Form 10-Q (2026) (opens in a new tab)
  45. EyePoint investor conferences and scientific meeting announcement (2026) (opens in a new tab)
  46. EyePoint investor presentation (2026) (opens in a new tab)
  47. EyePoint LUGANO expanded results presentation (2026) (opens in a new tab)
  48. EyePoint LUGANO topline results announcement (2026) (opens in a new tab)
  49. EyePoint LUGANO topline results presentation (2026) (opens in a new tab)
  50. EyePoint Pharmaceuticals DAVIO 2 enrollment completion announcement (2023) (opens in a new tab)
  51. EyePoint Pharmaceuticals DAVIO 2 protocol (2024) (opens in a new tab)
  52. EyePoint Pharmaceuticals DAVIO 2 topline results announcement (2023) (opens in a new tab)
  53. EyePoint Pharmaceuticals DAVIO 2 topline results presentation (2023) (opens in a new tab)
  54. EyePoint Pharmaceuticals DSMC recommendation announcement (2025) (opens in a new tab)
  55. EyePoint Pharmaceuticals Form 10-K (2025) (opens in a new tab)
  56. EyePoint Pharmaceuticals Investor Day presentation (2022) (opens in a new tab)
  57. EyePoint Pharmaceuticals investor presentation (2024) (opens in a new tab)
  58. EyePoint Pharmaceuticals LUCIA first patient dosed announcement (2024) (opens in a new tab)
  59. EyePoint Pharmaceuticals LUGANO enrollment completion announcement (2025) (opens in a new tab)
  60. EyePoint Pharmaceuticals LUGANO first patient dosed announcement (2024) (opens in a new tab)
  61. EyePoint Pharmaceuticals phase 3 enrollment completion announcement (2025) (opens in a new tab)
  62. EyePoint Pharmaceuticals R&D Day presentation (2024) (opens in a new tab)
  63. EyePoint second quarter 2026 results announcement (2026) (opens in a new tab)
  64. FDA Non-Inferiority Clinical Trials to Establish Effectiveness guidance (2016) (opens in a new tab)
  65. Flavin et al. (2024) (opens in a new tab)
  66. Fleckenstein et al. (2021) (opens in a new tab)
  67. Fonteh et al. (2022) (opens in a new tab)
  68. Franco et al. (2026) (opens in a new tab)
  69. Friedman et al. (2004) (opens in a new tab)
  70. GBD 2021 Global AMD Collaborators (2025) (opens in a new tab)
  71. Genentech LUCENTIS prescribing information (2024) (opens in a new tab)
  72. Genentech SUSVIMO prescribing information (2025) (opens in a new tab)
  73. Genentech VABYSMO prescribing information (2026) (opens in a new tab)
  74. Gohil et al. (2015) (opens in a new tab)
  75. Heier et al. (2022) (opens in a new tab)
  76. Holekamp et al. (2022) (opens in a new tab)
  77. Holz et al. (2015) (opens in a new tab)
  78. Holz et al. (2020) (opens in a new tab)
  79. Jackson et al. (2017) (opens in a new tab)
  80. Khurana et al. (2023) (opens in a new tab)
  81. Klein et al. (2007) (opens in a new tab)
  82. Kuznik et al. (2025) (opens in a new tab)
  83. Lanzetta et al. (2024) (opens in a new tab)
  84. Leandro et al. (2017) (opens in a new tab)
  85. Liu et al. (2024) (opens in a new tab)
  86. Loewenstein et al. (2024) (opens in a new tab)
  87. McGuire et al. (2026) (opens in a new tab)
  88. MedPAC (2026) (opens in a new tab)
  89. Monés et al. (2021) (opens in a new tab)
  90. National Eye Institute (2021) (opens in a new tab)
  91. Niazi et al. (2020) (opens in a new tab)
  92. NICE (2018) (opens in a new tab)
  93. Obeid et al. (2018) (opens in a new tab)
  94. Ocular Therapeutix first quarter 2026 results announcement (2026) (opens in a new tab)
  95. Ocular Therapeutix Form 10-Q (2026) (opens in a new tab)
  96. Ocular Therapeutix second quarter 2026 results announcement (2026) (opens in a new tab)
  97. Paneerselvam et al. (2026) (opens in a new tab)
  98. Patel (2018) (opens in a new tab)
  99. Patel and Ribeiro (2025) (opens in a new tab)
  100. Patel et al. (2024) (opens in a new tab)
  101. Pitsillidou et al. (2026) (opens in a new tab)
  102. Prenner et al. (2015) (opens in a new tab)
  103. Regeneron EYLEA HD prescribing information (2026) (opens in a new tab)
  104. Regeneron EYLEA prescribing information (2024) (opens in a new tab)
  105. Regillo (2024) (opens in a new tab)
  106. Rein et al. (2022) (opens in a new tab)
  107. Reitan et al. (2023) (opens in a new tab)
  108. Rosenfeld et al. (2006) (opens in a new tab)
  109. Rowe et al. (2025) (opens in a new tab)
  110. Rudnicka et al. (2015) (opens in a new tab)
  111. Sayed et al. (2024) (opens in a new tab)
  112. Schmidt et al. (2026) (opens in a new tab)
  113. Schmidt-Erfurth et al. (2014) (opens in a new tab)
  114. Shah (2026) (opens in a new tab)
  115. Sharma et al. (2000) (opens in a new tab)
  116. Sheth et al. (2024) (opens in a new tab)
  117. Siddiqui et al. (2022) (opens in a new tab)
  118. Siktberg et al. (2023) (opens in a new tab)
  119. Singh and Sørensen (2012) (opens in a new tab)
  120. Sivaprasad et al. (2025) (opens in a new tab)
  121. Sood et al. (2022) (opens in a new tab)
  122. Spaide et al. (2020) (opens in a new tab)
  123. Thomas et al. (2026) (opens in a new tab)
  124. Van Vu et al. (2024) (opens in a new tab)
  125. Varano et al. (2015) (opens in a new tab)
  126. Viola et al. (2024) (opens in a new tab)
  127. Vision Loss Expert Group of the Global Burden of Disease Study (2024) (opens in a new tab)
  128. Vu et al. (2021) (opens in a new tab)
  129. Vukicevic et al. (2016) (opens in a new tab)
  130. Windsor et al. (2018) (opens in a new tab)
  131. Wong et al. (2008) (opens in a new tab)
  132. Wong et al. (2014) (opens in a new tab)
  133. Wykoff (2024a) (opens in a new tab)
  134. Wykoff et al. (2024b) (opens in a new tab)
  135. Xu et al. (2026) (opens in a new tab)
  136. Zhang et al. (2023) (opens in a new tab)